Skip to main content

Table 6 Discontinuations for adverse events in >1% women randomized to duloxetine. Values are expressed as n (%).

From: Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial

 

Duloxetine

Placebo

P

 

(N = 60)

(N = 61)

 

For any adverse event

16 (26.7)

4 (6.6)

.003

Dizziness

4 (6.7)

2 (3.3)

.439

Nausea

2 (3.3)

0 (0.0)

.244

Somnolence

2 (3.3)

0 (0.0)

.244

Asthenia

1 (1.7)

0 (0.0)

.496

Flatulence

1 (1.7)

0 (0.0)

.496

Hypertension

1 (1.7)

0 (0.0)

.496

Insomnia

1 (1.7)

0 (0.0)

.496

Palpitations

1 (1.7)

0 (0.0)

.496

Phobia

1 (1.7)

0 (0.0)

.496

Urinary hesitation

1 (1.7)

0 (0.0)

.496

Vomiting

1 (1.7)

0 (0.0)

.496

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us